Pneumococcal

Use of both nutrition and treatment can help children and elderly populations, especially those in developing countries where vaccine availability is limited.

Serotype 19A is still the most prevalent serotype for pneumococcal disease, with study authors calling for additional studies to determine the full burden of invasive pneumococcal disease.

Pneumococcal serotype 3 was prevalent regardless of vaccination status, with the most common cases being in those with chronic lung disease.

Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.

Study authors suggest that saliva samples can be a complementary testing method to provide additional information on pneumococcal carriage and serotypes that may be undetected by nasopharyngeal testing.

Study data suggest that both vaccines induce similar functional antibody responses against pneumococcal serotype 3.

Study is the first to compare SARS-CoV-2–associated sepsis and presumed bacterial sepsis on mortality and incidence.

Community pharmacies and organizations can collaborate to tailor strategies and interventions and address the challenges and specific needs of the community.

By educating their patients on the provisions of the Inflation Reduction Act, pharmacists can have an even greater impact by increasing vaccine uptake in historically underserved groups.

Senate Bill 219 will also allow pharmacists to independently administer influenza and COVID-19 tests waived by the clinical laboratory improvement amendments.

Best practices to train staff and team members to engage patients and to ease the new vaccine offerings into the workflow are also discussed.

Pharmacists can play a crucial role in educating parents and helping remind them about the childhood vaccine schedule, which can be quite complex.

Investigators from Griffith University stated that technology has helped the development of vaccines that are safe to use and induce strong immune responses against Strep A.

Cost considerations for the rollout of new pneumococcal vaccines are discussed by a panel of medical experts.

Dr Schaffner underscores the significance of multidisciplinary teams in the effort to optimize vaccination rates for pneumococcal disease.

Christina Madison, PharmD, FCCP, AAHIVP, discusses disparities in patient populations directly influencing limited access to appropriate treatment and preventative care.

The significance of engaging patients and providing key educational points regarding pneumococcal vaccines is highlighted.

Antibiotic prescribing at hospital discharge is a component of pharmacist-led antimicrobial stewardship programs that is often overlooked.

Medical experts discuss clinical, social, and economic obstacles limiting pneumococcal vaccination efforts.

The panelists discuss the evolution of the pneumococcal vaccine landscape.

Study shows maternal vaccination with Pfizer’s hexavalent capsular polysaccharide conjugate vaccine may protect infants against Group B Streptococcus.

If approved, the V116 vaccine would be the first pneumococcal conjugate vaccine specifically designed for adults.

Secondary pneumococcal vaccine schedules are explored by Drs Schaffner, Bridgeman, and Madison.

Dr. Bridgeman highlights approved pneumococcal vaccines and their indications.

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, drives a discussion around preventative measures to limit the spread of pneumococcal infection.